ReviewDermatology and therapy2020
The Pathogenic Role of Demodex Mites in Rosacea: A Potential Therapeutic Target Already in Erythematotelangiectatic Rosacea?
Review in Dermatology and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 92 citations in OpenAlex.
- A Prospective Randomized Controlled Pilot Study to Assess the Response and Tolerability of Cold Atmospheric Plasma for Rosacea.Skin pharmacology and physiology · 2023Trial
- Demodex Infestation in Patients With Atopic Dermatitis Treated With Dupilumab: A Case-Control Study.The Journal of dermatology · 2026Article
- LC-OCT for Cutaneous Lupus Erythematosus: Characterization Across Disease Subtypes and Differentiation From Rosacea.Experimental dermatology · 2026Observational
- The Latest Advances in Rosacea Treatment: A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- The exposomal imprint on rosacea: More than skin deep.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Review
- Laser-Based Therapies in Rosacea: A Comprehensive Review of Mechanisms, Clinical Efficacy, and Future Directions.Journal of clinical medicine · 2026Review
- Sebum-Selective 1,726-nm Laser Therapy for Papulopustular Rosacea Associated withClinical, cosmetic and investigational dermatology · 2026Article
- Dermoscopic Response Predictors in Papulopustular Rosacea Treated with Topical Ivermectin and Metronidazole: A Prospective Observational Comparative Study.Clinical, cosmetic and investigational dermatology · 2026Article
- Efficacy of topical Ivermectin in controlling humanParasite epidemiology and control · 2025Article
- The role of skin barrier and immune abnormalities in the pathogenesis of Rosacea.Clinical and experimental medicine · 2025Review
- The Role of Skin Microbiota in Facial Dermatoses and Related Factors: A Narrative Review.International journal of molecular sciences · 2025Review
- Review
- Article
- A Cross-Sectional Survey of the Relationship between Rosacea andJournal of arthropod-borne diseases · 2025Article
- Ocular Rosacea: An Updated Review.Cornea · 2025Review
- The effect of rosacea on neurodegenerative and neuropsychiatric diseases: a two-sample Mendelian randomization study.Archives of dermatological research · 2025Article
- Advances in the pathogenesis of rosacea.Frontiers in immunology · 2025Review
- An Overview of the Skin Microbiome, the Potential for Pathogen Shift, and Dysbiosis in Common Skin Pathologies.Microorganisms · 2025Review
- Comparison of the Skin Microbiota in the Periocular Region between Patients with Inflammatory Skin Diseases and Healthy Participants: A Preliminary Study.Life (Basel, Switzerland) · 2024Article
- Predicting host range expansion in parasitic mites using a global mammalian-acarine dataset.Nature communications · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rosacea is a common facial dermatosis but its definition and classification are still unclear, especially in terms of its links with demodicosis. Triggers of rosacea (ultraviolet light, heat, spicy foods, alcohol, stress, microbes) are currently considered to induce a cascading innate and then adaptive immune response that gets out of control. Recent histological and biochemical studies support the concept that this inflammatory response is a continuum, already present from the onset of the disease, even when no clinical signs of inflammation are visible. The Demodex mite is beginning to be accepted as one of the triggers of this inflammatory cascade, and its proliferation as a marker of rosacea; moreover, the papulopustules of rosacea can be effectively treated with topical acaricidal agents. Demodex proliferation appears to be a continuum process in rosacea, and may not be clinically visible at the onset of the disease. Molecular studies suggest that Demodex may induce tolerogenic dendritic cells and collaborate with vascular endothelial growth factor (VEGF) to induce T cell exhaustion and favor its own proliferation. These interactions among VEGF, Demodex, and immunity need to be explored further and the nosology of rosacea adapted accordingly. However, treating early rosacea, with only clinically visible vascular symptoms, with an acaricide may decrease early inflammation, limit potential flare-ups following laser treatment, and prevent the ultimate development of the papulopustules of rosacea. The effectiveness of this approach needs to be confirmed by prospective controlled clinical trials with long-term follow-up. Currently, the evidence suggests that patients with only vascular symptoms of rosacea should be carefully examined for the presence of follicular scales as signs of Demodex overgrowth or pityriasis folliculorum so that these patients, at least, can be treated early with an acaricidal cream.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.